Preliminary data from a Phase 1b dose escalation study of OP-1250, an oral CERAN, in combination with palbociclib in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

被引：0
|
作者：
Chan, Arlene
Day, Daphne
Hui, Rina
McCarthy, Nicole
Wilson, Rosalind
Faltaos, Demiana
Shaw, Morena
Murphy, Caitlin
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P3-07-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-15
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.
    Lim, Elgene
    Jhaveri, Komal L.
    Perez-Fidalgo, Jose Alejandro
    Bellet, Meritxell
    Boni, Valentina
    Garcia, Jose Manuel Perez
    Estevez, Laura
    Bardia, Aditya
    Turner, Nicholas C.
    Villanueva, Rafael
    Cobo, Sara Lopez-Tarruella
    Im, Seock-Ah
    Kim, Sung-Bae
    Gates, Mary R.
    Monemi, Sharareh
    Chen, Ya-Chi
    Moore, Heather
    Loi, Sherene
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer
    Hamilton, Erika
    Pusztai, Lajos
    Soliman, Hatem H.
    Hurvitz, Sara
    Grzegorzewski, Krzysztof
    Habboubi, Nassir
    Marreddy, Priya
    Sahmoud, Tarek
    Ibrahim, Nuhad
    CANCER RESEARCH, 2023, 83 (05)
  • [23] Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
    Jhaveri, Komal L.
    Bellet, Meritxell
    Turner, Nicholas C.
    Loi, Sherene
    Bardia, Aditya
    Boni, Valentina
    Sohn, Joohyuk
    Neilan, Tomas G.
    Villanueva-Vazquez, Rafael
    Kabos, Peter
    Garcia-Estevez, Laura
    Lopez-Miranda, Elena
    Perez-Fidalgo, J. Alejandro
    Perez-Garcia, Jose M.
    Yu, Jiajie
    Fredrickson, Jill
    Moore, Heather M.
    Chang, Ching-Wei
    Bond, John W.
    Eng-Wong, Jennifer
    Gates, Mary R.
    Lim, Elgene
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 754 - 766
  • [24] Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
    Johnston, Stephen R. D.
    Pluard, Timothy J.
    Wang, Judy S.
    Hamilton, Erika P.
    Juric, Dejan
    Scholz, Catherine Rose
    Hnitecki, Elizabeth
    Gao, Lei
    Cantagallo, Lisa
    Korpal, Manav
    Destenaves, Benoit
    Xiao, Jianjun Alan
    Zhang, Zhaojie
    Pipas, J. Marc Marc
    Yu, Lihua
    Sahmoud, Tarek
    Gualberto, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancer
    Abramson, V.
    Linden, H. M.
    Crew, K.
    Mortimer, J.
    Alidzanovic, J.
    Nangia, J.
    Layman, R.
    Vranjes, Z. J.
    Andric, Z.
    Milovic-Kovacevic, M.
    Trifunovic, J.
    Karchmit, Y.
    Suarez, J.
    Suster, M.
    Ptaszynski, M.
    Chalasani, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S619 - S619
  • [26] PALVEN: A phase 1b study of palbociclib, letrozole and venetoclax in estrogen receptor, BCL2-positive metastatic breast cancer
    Muttiah, Christine
    Travers, Avraham
    Whittle, James R.
    Dawson, Sarah-Jane
    Yeo, Belinda
    Visvader, Jane E.
    Oakman, Catherine
    Lindeman, Geoffrey J.
    CANCER RESEARCH, 2021, 81 (04)
  • [27] Results from a dose escalation phase 1b study of palbociclib and avelumab in advanced breast cancer in the PAveMenT Trial
    Okines, Alicia F.
    Moghadam, Houman
    Sparks, Laura
    Mohammed, Kabir
    Dunne, Kathryn
    Nerurkar, Ashutosh
    Osin, Peter
    Swift, Claire
    Sardinha, Ruth
    Turner, Nicholas
    CANCER RESEARCH, 2023, 83 (05)
  • [28] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
    Hamilton, Erika
    Kim, Sung-Bae
    Lin, Nancy U.
    Awada, Ahmad
    Gil, Eva Ciruelos
    Di Sanzo, Alessandro
    Vallespir, Bartomeu Piza
    Theall, Kathy Puyana
    Ibrahim, Nuhad
    CANCER RESEARCH, 2024, 84 (07)
  • [29] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
    Hamilton, Erika
    Kim, Sung-Bae
    Awada, Ahmad
    Lin, Nancy
    Zuefle, Sebastian
    Scartoni, Simona
    Vallespir, Bartomeu Piza
    Theall, Kathy Puyana
    Ibrahim, Nuhad
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 30 - 31
  • [30] A phase I study of RAD1901, an oral selective estrogen receptor degrader, in ER-positive, HER2-negative, postmenopausal advanced breast cancer patients.
    Harb, Wael A.
    Garner, Fiona
    Clarkin, Marcie
    Roberge, Kathleen A.
    Harris, Alan G.
    Williams, Gregory
    Hattersley, Gary
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345